title: MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma.
abstract: The aim of this study was to detect MTA2 expression in pancreatic ductal adenocarcinoma (PDA) and to analyze its association with prognosis of PDA patients. MTA2 mRNA and protein expression were determined by real-time quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry in specimens of primary cancer and their adjacent noncancerous tissues in PDA patients. We found that MTA2 mRNA and protein expression levels were both significantly upregulated in PDA lesions compared with adjacent noncancerous tissues. Immunohistochemistry showed that high MTA2 expression was correlated with poor tumor differentiation, TNM stage, and lymph node metastasis. Kaplan-Meier survival analysis showed that patients with high expression levels of MTA2 showed lower overall survival rate than those with low expression levels. Multivariate analysis showed that high MTA2 protein expression was an independent prognostic factor for PDA patients. Our study suggests that overexpression of MTA2 may play an important role in the progression of PDA and MTA2 expression may serve as a biomarker for poor prognosis for PDA.
authors: Department of Gastroenterology, The PLA 117 Hospital, No. 14, Lingyin Rd., Hangzhou, 310013, China.
authors: Da-Wei
authors: DW
authors: Chen
authors: Yao-Fu
authors: YF
authors: Fan
authors: Jiang
authors: J
authors: Li
authors: Xiao-Xiao
authors: XX
authors: Jiang
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D021441:Carcinoma, Pancreatic Ductal / Q000235:genetics / Q000378:metabolism / Q000401:mortality*; D005260:Female; D006655:Histone Deacetylases / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010179:Pancreas / Q000378:metabolism* / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000401:mortality*; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D012097:Repressor Proteins; C120917:MTA2 protein, human; D006655:Histone Deacetylases
references: J Clin Oncol. 2001 Jul 1;19(13):3210-8
references: 11432888
references: J Biol Chem. 2003 Oct 24;278(43):42560-8
references: 12920132
references: J Exp Clin Cancer Res. 2000 Mar;19(1):105-11
references: 10840944
references: Clin Cancer Res. 2006 Mar 1;12(5):1479-86
references: 16533771
references: Clin Exp Metastasis. 2003;20(1):19-24
references: 12650603
references: Eur J Surg Oncol. 2007 Apr;33(3):266-70
references: 17097848
references: Lancet Oncol. 2004 Jun;5(6):341-53
references: 15172354
references: Am J Pathol. 2002 May;160(5):1745-54
references: 12000726
references: N Engl J Med. 1992 Jun 25;326(26):1782
references: 1375706
references: Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3
references: 12023793
references: J Biol Chem. 2002 Sep 20;277(38):35434-9
references: 12124384
references: Mol Endocrinol. 2004 Dec;18(12):2937-49
references: 15358836
references: Mol Endocrinol. 2006 Sep;20(9):2020-35
references: 16645043
references: Am J Surg. 2003 Nov;186(5):486-92
references: 14599612
references: Mol Cancer. 2005 Jun 21;4(1):21
references: 15969750
references: Gut. 2007 Jan;56(1):140-8
references: 16840508